Clinical Trial Update: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated two dosing regimens of fostamatinib versus placebo in rheumatoid arthritis patients on DMARDs who did not respond; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: AstraZeneca | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2014-04-17